Home / ATRA : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does ATRA make money? Does ATRA have pricing power? What's the Earnings Whisper? Will ATRA profit more as the business scales? What is ATRA's management track record? Is ATRA's current price justified?

Atara Biotherapeutics, Inc.

$9.25 -$8.52 (-47.95%)

NASDAQ · 14 Sep 2026 20:00 UTC

Previous Close

$9.38

Day Range

$9.09$9.66

Year Range

$3.92$19.14

Market Cap

83.34M

AVG Volume

1.43M

Trailing/Forward PE

-7.84/9.83

PEG ratio

0.03

Dividend Yield

Next Earnings Date

2026-11-11

Primary Exchange

NASDAQ

Revenue (USD) · TTM

ATRA Revenue (USD) · TTM by quarter
Period	Revenue (USD) · TTM
26 Q2	6.19M
26 Q1	23.14M
25 Q4	120.77M
25 Q3	151.93M
25 Q2	188.67M
25 Q1	199.73M
24 Q4	128.94M
24 Q3	100.44M
24 Q2	62.39M
24 Q1	34.7M

Net Income (USD) · TTM

ATRA Net Income (USD) · TTM by quarter
Period	Net Income (USD) · TTM
26 Q2	-16.69M
26 Q1	-9.47M
25 Q4	32.69M
25 Q3	23.4M
25 Q2	5.79M
25 Q1	-15.64M
24 Q4	-85.4M
24 Q3	-133.16M
24 Q2	-181.05M
24 Q1	-233.11M

Operating Income (USD) · TTM

ATRA Operating Income (USD) · TTM by quarter
Period	Operating Income (USD) · TTM
26 Q2	-14.23M
26 Q1	-6.31M
25 Q4	35.86M
25 Q3	26.22M
25 Q2	8.04M
25 Q1	-13.39M
24 Q4	-83.44M
24 Q3	-124.51M
24 Q2	-172.37M
24 Q1	-225.55M

EBITDA (USD) · TTM

ATRA EBITDA (USD) · TTM by quarter
Period	EBITDA (USD) · TTM
26 Q2	-13.65M
26 Q1	-5.48M
25 Q4	38.63M
25 Q3	30.5M
25 Q2	14.31M
25 Q1	-5.74M
24 Q4	-75.75M
24 Q3	-123.21M
24 Q2	-170.91M
24 Q1	-222.98M

Cash Flows (USD) · TTM

ATRA Cash Flows (USD) · TTM by quarter
Period	Cash Flows (USD) · TTM
26 Q2	-21.89M
26 Q1	-25.88M
25 Q4	-50.94M
25 Q3	-69.8M
25 Q2	-64.01M
25 Q1	-67.36M
24 Q4	-68.96M
24 Q3	-94.85M
24 Q2	-142.49M
24 Q1	-185.11M

EPS (USD) · TTM

ATRA EPS (USD) · TTM by quarter
Period	EPS (USD) · TTM
26 Q2	-1.18
26 Q1	-0.67
25 Q4	3.12
25 Q3	2.18
25 Q2	-0.43
25 Q1	-3.72
24 Q4	-12.87
24 Q3	-25.66
24 Q2	-39.13
24 Q1	-52.94

Expenses (USD) · TTM

ATRA Expenses (USD) · TTM by quarter
Period	Expenses (USD) · TTM
26 Q2	19.89M
26 Q1	27.97M
25 Q4	63.12M
25 Q3	97.32M
25 Q2	144.75M
25 Q1	173.78M
24 Q4	191.62M
24 Q3	207.78M
24 Q2	222.85M
24 Q1	250.55M

Shares Outstanding (USD) · TTM

ATRA Shares Outstanding (USD) · TTM by quarter
Period	Shares Outstanding (USD) · TTM
26 Q2	-3.88M
26 Q1	-6.29M
25 Q4	-9.75M
25 Q3	-14.08M
25 Q2	-19.28M
25 Q1	-22.81M
24 Q4	-27M
24 Q3	-31.08M
24 Q2	-35.8M
24 Q1	-42.02M

Employee Count

ATRA Employee Count by quarter
Period	Employee Count
2025	14
2024	153
2023	225
2022	334
2021	578
2020	437
2019	393
2018	311
2017	185
2016	96

PE Ratio

ATRA PE Ratio by quarter
Period	PE Ratio
May 26	3.2
May 26	1.88
Apr 26	1.92
Apr 26	2.02
Apr 26	1.78
Apr 26	1.91
Mar 26	1.76
Mar 26	1.88
Mar 26	3.77
Mar 26	3
Feb 26	3.14
Feb 26	2.42
Feb 26	2.58
Feb 26	2.83
Jan 26	3.01
Jan 26	3.03
Jan 26	2.63
Jan 26	7.92
Jan 26	10.3
Dec 25	10.01
Dec 25	9.95
Dec 25	10.43
Dec 25	8.31
Nov 25	8.75
Nov 25	7.93
Nov 25	7.98
Nov 25	24.86
Oct 25	31.26
Oct 25	30.5
Oct 25	31.17
Oct 25	30.16
Oct 25	30.33
Sep 25	28.92
Sep 25	25.36
Sep 25	25.51
Sep 25	27.17
Aug 25	25.36
Aug 25	25.97
Aug 25	25.87

Free Cash Flow Yield

ATRA Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-15.75%
Sep 26	-15.53%
Sep 26	-14.92%
Aug 26	-15.83%
Aug 26	-15.02%
Aug 26	-18%
Aug 26	-21.75%
Jul 26	-21.93%
Jul 26	-23.26%
Jul 26	-21.9%
Jul 26	-18.83%
Jul 26	-15.77%
Jun 26	-17.48%
Jun 26	-18.25%
Jun 26	-17.65%
Jun 26	-18.52%
May 26	-17.48%
May 26	-18.75%
May 26	-19.18%
May 26	-48.69%
May 26	-82.88%
Apr 26	-81.06%
Apr 26	-77.06%
Apr 26	-87.33%
Apr 26	-81.38%
Mar 26	-88.47%
Mar 26	-82.71%
Mar 26	-79.17%
Mar 26	-99.54%
Feb 26	-94.95%
Feb 26	-123.12%
Feb 26	-115.65%
Feb 26	-105.46%
Jan 26	-98.97%
Jan 26	-98.59%
Jan 26	-113.35%
Jan 26	-37.65%
Jan 26	-28.96%
Dec 25	-29.8%
Dec 25	-29.97%
Dec 25	-28.59%
Dec 25	-35.91%
Nov 25	-34.08%
Nov 25	-37.62%
Nov 25	-37.4%
Nov 25	-44.43%
Oct 25	-35.34%
Oct 25	-36.22%
Oct 25	-35.43%
Oct 25	-36.62%
Oct 25	-36.42%
Sep 25	-38.19%
Sep 25	-43.55%
Sep 25	-43.3%
Sep 25	-40.65%
Aug 25	-43.55%
Aug 25	-42.53%
Aug 25	-42.7%
Aug 25	-57.1%
Aug 25	-54.18%
Jul 25	-54.04%
Jul 25	-62.58%
Jul 25	-67.8%
Jul 25	-73.89%
Jun 25	-78.62%
Jun 25	-78.82%
Jun 25	-70.95%
Jun 25	-67.8%
May 25	-80.23%
May 25	-87.65%
May 25	-91.49%
May 25	-88.74%
May 25	-82.5%
Apr 25	-88.13%
Apr 25	-104.56%
Apr 25	-116.66%
Apr 25	-115.41%
Mar 25	-98.79%
Mar 25	-97.3%
Mar 25	-88.98%
Mar 25	-93.5%
Feb 25	-183.86%
Feb 25	-178.69%
Feb 25	-147.9%
Feb 25	-126.29%
Jan 25	-143.07%
Jan 25	-154.56%
Jan 25	-193.37%
Jan 25	-81.7%
Jan 25	-77.7%
Dec 24	-104.56%
Dec 24	-111.44%
Dec 24	-122.99%
Dec 24	-97.5%
Nov 24	-104.31%
Nov 24	-110.76%
Nov 24	-105.87%
Nov 24	-205.09%
Nov 24	-238.88%
Oct 24	-269.72%

Price to Sales

ATRA Price to Sales by quarter
Period	Price to Sales
Sep 26	22.45
Sep 26	22.77
Sep 26	23.69
Aug 26	22.33
Aug 26	23.54
Aug 26	19.63
Aug 26	5.14
Jul 26	5.1
Jul 26	4.81
Jul 26	5.11
Jul 26	5.94
Jul 26	7.09
Jun 26	6.4
Jun 26	6.13
Jun 26	6.33
Jun 26	6.04
May 26	6.4
May 26	5.96
May 26	5.83
May 26	0.87
May 26	0.51
Apr 26	0.52
Apr 26	0.55
Apr 26	0.48
Apr 26	0.52
Mar 26	0.48
Mar 26	0.51
Mar 26	0.58
Mar 26	0.46
Feb 26	0.48
Feb 26	0.37
Feb 26	0.4
Feb 26	0.44
Jan 26	0.46
Jan 26	0.47
Jan 26	0.41
Jan 26	1.22
Jan 26	1.59
Dec 25	1.54
Dec 25	1.53
Dec 25	1.61
Dec 25	1.28
Nov 25	1.35
Nov 25	1.22
Nov 25	1.23
Nov 25	0.76
Oct 25	0.96
Oct 25	0.94
Oct 25	0.96
Oct 25	0.93
Oct 25	0.93
Sep 25	0.89
Sep 25	0.78
Sep 25	0.78
Sep 25	0.83
Aug 25	0.78
Aug 25	0.8
Aug 25	0.79
Aug 25	0.59
Aug 25	0.62
Jul 25	0.62
Jul 25	0.54
Jul 25	0.5
Jul 25	0.46
Jun 25	0.43
Jun 25	0.43
Jun 25	0.48
Jun 25	0.5
May 25	0.42
May 25	0.38
May 25	0.37
May 25	0.6
May 25	0.65
Apr 25	0.61
Apr 25	0.51
Apr 25	0.46
Apr 25	0.46
Mar 25	0.54
Mar 25	0.55
Mar 25	0.6
Mar 25	0.57
Feb 25	0.51
Feb 25	0.53
Feb 25	0.64
Feb 25	0.75
Jan 25	0.66
Jan 25	0.61
Jan 25	0.49
Jan 25	1.16
Jan 25	1.22
Dec 24	0.9
Dec 24	0.85
Dec 24	0.77
Dec 24	0.97
Nov 24	0.91
Nov 24	0.85
Nov 24	0.89
Nov 24	1.11
Nov 24	0.96
Oct 24	0.85

EV/EBITDA

ATRA EV/EBITDA by quarter
Period	EV/EBITDA
May 26	3.86
May 26	2.74
Apr 26	2.77
Apr 26	2.86
Apr 26	2.66
Apr 26	2.77
Mar 26	2.64
Mar 26	2.74
Mar 26	4.36
Mar 26	3.77
Feb 26	3.88
Feb 26	3.33
Feb 26	3.45
Feb 26	3.64
Jan 26	3.79
Jan 26	3.79
Jan 26	3.49
Jan 26	7.55
Jan 26	9.38
Dec 25	9.15
Dec 25	9.11
Dec 25	9.48
Dec 25	7.85
Nov 25	8.19
Nov 25	7.56
Nov 25	7.59
Nov 25	9.74
Oct 25	12.33
Oct 25	12.02
Oct 25	12.3
Oct 25	11.89
Oct 25	11.96
Sep 25	11.38
Sep 25	9.94
Sep 25	10
Sep 25	10.68
Aug 25	9.94
Aug 25	10.19
Aug 25	10.15

Price to Book

ATRA Price to Book by quarter
Period	Price to Book
Oct 23	17.62
Oct 23	19.32
Oct 23	21.71
Oct 23	19.88
Sep 23	20.87
Sep 23	25.24
Sep 23	21.57
Sep 23	21.57
Sep 23	21.85
Aug 23	20.02
Aug 23	21.01
Aug 23	29.47
Aug 23	3.68
Jul 23	3.3
Jul 23	3.36
Jul 23	2.93
Jul 23	2.96
Jun 23	2.58
Jun 23	2.82
Jun 23	3.22
Jun 23	3.17
Jun 23	2.46
May 23	2.83
May 23	3.38
May 23	3.43
May 23	2.37
Apr 23	2.21
Apr 23	2.48
Apr 23	2.19
Apr 23	2.26
Mar 23	2.36
Mar 23	2.34
Mar 23	2.46
Mar 23	2.31
Mar 23	2.94
Feb 23	3.31
Feb 23	3.68
Feb 23	3.47
Feb 23	2.83
Jan 23	2.88
Jan 23	2.13
Jan 23	2.13
Jan 23	1.92
Dec 22	1.8
Dec 22	1.64
Dec 22	1.93
Dec 22	2.44
Dec 22	2.61
Nov 22	2.29
Nov 22	2.34
Nov 22	2.81
Nov 22	1.89
Oct 22	1.92
Oct 22	1.69
Oct 22	1.49
Oct 22	1.52
Sep 22	1.51
Sep 22	1.32
Sep 22	1.61
Sep 22	1.92
Sep 22	1.71
Aug 22	1.61
Aug 22	1.77
Aug 22	2.33
Aug 22	1.54
Jul 22	1.36
Jul 22	1.45
Jul 22	1.73
Jul 22	3.82
Jul 22	3.73
Jun 22	3.28
Jun 22	2.64
Jun 22	2.34
Jun 22	2.31
May 22	2.34
May 22	2.32
May 22	2.46
May 22	3.11
Apr 22	2.22
Apr 22	2.53
Apr 22	2.79
Apr 22	3.05
Apr 22	3.31
Mar 22	3.27
Mar 22	3.41
Mar 22	3.14
Mar 22	3.08
Feb 22	3.98
Feb 22	3.96
Feb 22	4.39
Feb 22	4.41
Jan 22	4.48
Jan 22	4.22
Jan 22	4.85
Jan 22	4.74
Dec 21	4.76
Dec 21	5.22
Dec 21	4.57
Dec 21	4.82
Dec 21	5.16

No video analysis for this stock yet. Request one from our team.

News: ATRA

businesswire.com · 12 Aug 2026

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2026 and business updates. “This was an important quarter for Atara. We and our partners, Pierre Fabre Pharmaceuticals (PFP), had a productive Type A meeting with the.

AI Analysis

Atara Biotherapeutics, Inc.

Video analysis: ATRA

News: ATRA

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

Similar companies